Press Releases
-
Jun 5, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development, will present at the Goldman Sachs 40th Annual Global Healthcare...
-
Jun 4, 2019First and Only Treatment in China Approved for Patients with This Ultra-Rare Genetic Condition
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Vimizim® (elosulfase alfa) has been approved by the National Medical Products Administration (NMPA) for the treatment of patients...
-
May 28, 2019Timing of Regulatory Submissions to Be Determined in 3Q 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A achieved pre-specified clinical...
-
May 28, 2019Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene...
-
May 27, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will host a conference call and webcast on Tuesday, May 28 at 8:00am ET to discuss program updates. Conference Call and...
-
May 16, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Robert Baffi, Ph.D., Executive Vice President, Technical Operations, will participate in a gene therapy manufacturing focused...
-
May 8, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care...
-
May 6, 2019First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Commission (EC) has granted marketing authorization for Palynziq® (pegvaliase injection) at doses of up to 60 mg once...
-
Apr 25, 2019- Total Revenues Top $400 million in the Quarter
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2019 2018 % Change Total Revenues $ 400.7 $ 373.4 7% Net Product Revenues Marketed...
Apr 17, 2019Company Ranks 1st Among Midsize Employers in 'Drugs & Biotechnology' IndustryBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51st on last year's...
-
Apr 2, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Mar 6, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Cowen and Company Health Care Conference on...
-
Mar 1, 2019Decision on Marketing Authorization Application Expected Q2 '19
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has...
-
Feb 21, 2019- Total Revenues for 2018 Grow 14% Year-over-Year to $1.5 Billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2018 2017 % Change 2018 2017 % Change Total...
-
Feb 7, 2019Reduced Rate of Decline Maintained in Children with CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that an ongoing open-label extension study treating patients with Brineura® (cerliponase alfa) continued to show a reduced rate of...
-
Feb 4, 2019Presentations to Highlight Results from Studies for the Treatment of Three Forms of MPS and CLN2 Disease, a Form of Batten Disease
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four platform and 10 poster presentations at the 15th Annual WORLDSymposiumTM being held February...
-
Jan 23, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Jan 7, 2019Completed Enrollment of Subject Cohort to Support BLA Submission Through Accelerated Approval (AA) Pathway for Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a company focused on innovative therapies to treat rare diseases, provided highlights to the investment community on its key milestones for 2019 at the...
-
Dec 18, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 37th Annual J.P. Morgan Healthcare Conference...
-
Dec 3, 2018
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Amy Wireman to Group Vice President, Human Resources. Ms. Wireman's promotion to lead the Human Resources function...
-
Dec 3, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's 13th Annual Biotech Conference on December 5 in New York City. To access the live webcast,...
-
Nov 12, 2018First-of-its-Kind Musical Featuring 25 High-School Students Affected by Bleeding Disorders Premieres in Broadway Theater
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a...
-
Nov 8, 2018- Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in two investor conferences this November. To access the events that are accessible by live webcasts,...
-
Nov 7, 2018Vosoritide for Achondroplasia: Demonstrates Continued Increased Growth through 42 months in Phase 2; Global Phase 3 Fully Enrolled
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare and...
-
Nov 1, 2018Key Research & Development Pipeline Products and Data to be Presented, Including:
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday, November 7, 2018 in New York City. BioMarin management and external experts will...
